丹麦全国队列研究2000-2018:使用保类固醇药物治疗炎症性肠病与发病年龄相关
该丹麦全国队列研究纳入2000-2018年确诊的克罗恩病和溃疡性结肠炎患者,按发病年龄分组比较使用保类固醇药物的模式。结果显示儿童期发病者更常用免疫调节剂和生物制剂,而老年期发病者使用保类固醇药物较少,高衰弱状态可能部分解释老年期发病者的差异。
要点
- 儿童期发病的克罗恩病和溃疡性结肠炎患者使用免疫调节剂和生物制剂的比例高于成人期发病者。
- 老年期发病的克罗恩病和溃疡性结肠炎患者使用免疫调节剂和生物制剂的比例低于成人期发病者。
- 即使经过两个疗程全身性类固醇治疗后,老年期发病者仍较少使用保类固醇药物。
核心结论
- 不同发病年龄组之间使用保类固醇药物存在显著差异,即使经过两个疗程全身性类固醇治疗后仍存在差异。
- 高衰弱状态可能部分解释老年期发病炎症性肠病患者的这些差异。
研究设计与样本
- 通过丹麦医疗登记系统识别2000年至2018年间确诊的克罗恩病或溃疡性结肠炎患者。
- 患者根据诊断时年龄分组,比较儿童期发病、老年期发病与成人期发病的炎症性肠病。
- 使用Kaplan-Meier图描述诊断后及第一、第二疗程全身性类固醇治疗后的药物和手术情况。
- 使用多因素Cox回归分析计算保类固醇药物的风险比(HR)和95%置信区间(CI)。
主要发现
- 1851例(13%)克罗恩病和1687例(6%)溃疡性结肠炎患者为儿童期发病,2952例(20%)克罗恩病和5812例(23%)溃疡性结肠炎患者为老年期发病。
- 与成人期发病组相比,儿童期发病组更频繁使用免疫调节剂(克罗恩病:HR 1.64,95%CI 1.52-1.77;溃疡性结肠炎:HR 2.29,95%CI 2.02-2.61)和生物制剂(克罗恩病:HR 1.43,95%CI 1.25-1.65;溃疡性结肠炎:HR 1.27,95%CI 0.99-1.64)。
- 与成人期发病组相比,老年期发病组较少使用免疫调节剂(克罗恩病:HR 0.39,95%CI 0.35-0.44;溃疡性结肠炎:HR 0.58,95%CI 0.50-0.67)和生物制剂(克罗恩病:HR 0.19,95%CI 0.14-0.25;溃疡性结肠炎:HR 0.36,95%CI 0.27-0.48)。
- 经过两个疗程全身性类固醇治疗后,老年期发病组仍较少使用保类固醇药物。
- 高衰弱状态与老年期发病组使用药物较少相关。
关键数值与推荐
- 儿童期发病组与成人期发病组相比,使用免疫调节剂的克罗恩病HR为1.64(95%CI 1.52-1.77),溃疡性结肠炎HR为2.29(95%CI 2.02-2.61)。
- 儿童期发病组与成人期发病组相比,使用生物制剂的克罗恩病HR为1.43(95%CI 1.25-1.65),溃疡性结肠炎HR为1.27(95%CI 0.99-1.64)。
- 老年期发病组与成人期发病组相比,使用免疫调节剂的克罗恩病HR为0.39(95%CI 0.35-0.44),溃疡性结肠炎HR为0.58(95%CI 0.50-0.67)。
- 老年期发病组与成人期发病组相比,使用生物制剂的克罗恩病HR为0.19(95%CI 0.14-0.25),溃疡性结肠炎HR为0.36(95%CI 0.27-0.48)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Paediatric-onset and elderly-onset inflammatory bowel disease (IBD) present unique treatment challenges. AIMS: We investigated treatment patterns following a first and second course of systemic steroids in paediatric- and elderly-onset IBD and compared them to adult-onset IBD. METHODS: All patients diagnosed with Crohn's disease (CD) or ulcerative colitis (UC) between 2000 and 2018 were identified through the Danish healthcare registries. Patients were divided into groups based on their age at diagnosis. Kaplan-Meier plots were prepared for medications and surgeries after diagnosis and after the first and second courses of systemic steroids. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated using multivariate Cox regression analysis for steroid-sparing medications. RESULTS: 1851 CD (13%) and 1687 (6%) UC patients were paediatric-onset, while 2952 (20%) CD and 5812 (23%) UC patients were elderly-onset. Paediatric-onset more frequently received immunomodulators [CD: HR: 1.64, CI: 1.52-1.77, UC: HR: 2.29, CI: 2.02-2.61] and biologics [CD: HR: 1.43, CI: 1.25-1.65, UC: HR: 1.27, CI: 0.99-1.64], while elderly-onset less frequently received immunomodulators [CD: HR: 0.39, CI: 0.35-0.44, UC: HR: 0.58, CI: 0.50-0.67] and biologics [CD: HR: 0.19, CI: 0.14-0.25, UC: HR: 0.36, CI: 0.27-0.48] compared to adult-onset age groups. After two courses of systemic steroids, elderly-onset still received less steroid-sparing medications. High frailty was associated with lower usage of medications for elderly-onset. CONCLUSION: There are significant differences in the use of steroid-sparing medication between age of onset, even after two courses with systemic steroids. High frailty could account for some of these differences in elderly-onset IBD.
引用
- Nordestgaard RLM, Wewer MD, Malham M, et al. Treatment of inflammatory bowel disease with steroid-sparing medications is age-dependent - Results from a Danish nationwide cohort study, 2000-2018. Aliment Pharmacol Ther. 2024. PMID: 38859674. doi:10.1111/apt.18106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。